Knowing when to sell: How growth investor Michael Frazis manages risk

Michael Frazis is back to unpack a market moving faster than ever. From cracks appearing in the AI infrastructure trade and a potential software comeback, to personalised cancer vaccines and the evolution of his own investing strategy, Michael explains why he’s moved from simply holding great growth companies to systematically taking profits and managing momentum. Plus, we dig into Nvidia’s biggest long-term threat, why Apple may have played the AI boom perfectly, and the thinking behind Frazis Capital Partners’ new ROAR Active ETF.

In this episode:

00:00 Why markets could be entering a more volatile era

02:27 The AI trade, leverage & the Ashenbrenner blow-up

08:11 Is the AI infrastructure boom starting to crack?

12:25 Cheaper AI models, China & why Apple may be the winner

16:50 The software comeback & where Michael sees opportunities

22:17 Michael Frazis’ new rules for growth & momentum investing

39:25 GLP-1s, Moderna & the next wave of biotech breakthroughs

46:49 Why Frazis Capital launched the ROAR Active ETF

Stocks & ETFs Mentioned: Frazis Capital Partners ROAR Active ETF (ASX: ROAR), Nvidia (NASDAQ: NVDA), Broadcom (NASDAQ: AVGO), Apple (NASDAQ: AAPL), Alphabet (NASDAQ: GOOGL), Meta Platforms (NASDAQ: META), Amazon (NASDAQ: AMZN), Microsoft (NASDAQ: MSFT), Taiwan Semiconductor Manufacturing Company (NYSE: TSM), Alibaba Group (NYSE: BABA), Atlassian (NASDAQ: TEAM), WiseTech Global (ASX: WTC), Xero (ASX: XRO), REA Group (ASX: REA), Datadog (NASDAQ: DDOG), Tesla (NASDAQ: TSLA), AMD (NASDAQ: AMD), Palantir Technologies (NASDAQ: PLTR), Wesfarmers (ASX: WES), Commonwealth Bank (ASX: CBA), Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), Moderna (NASDAQ: MRNA), Tempus AI (NASDAQ: TEM), Clarity Pharmaceuticals (ASX: CU6)

Check out Lioncrest's new ETF ROAR here: https://lioncrestpartners.com/#roar-etf